( sion proteins. These are combin...)Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting,Health

sion proteins. These are combinations of vascular targeting agents such as bavituximab and immune system-stimulating cytokines such as interferon and interleukin-2. Peregrine's immunocytokine fusion proteins showed robust anti-tumor efficacy in animal models of melanoma and B-cell lymphoma, without the signs of toxicity that have limited the wide use of cytokines as anti-cancer agents. In particular, the 85% reduction in tumor growth observed in the B-cell lymphoma model serves as an important validation of Peregrine's VTA immunocytokine approach, and hematological cancers such as lymphoma also represent potential new cancer indications for the company.

Data on Peregrine's VTA coaguligand and VEA anti-cancer development programs.

Researchers working with Peregrine presented data on progress in the company's VTA coaguligand development program, its VEA program and its initiatives to develop second-generation anti-PS monoclonal antibodies.

    *  Peregrine's VTA coaguligands program has developed fusion proteins that

       combine a vascular targeting antibody with modified tissue factor, a

       protein that can induce blocking and destruction of targeted blood

       vessels.  Since Peregrine's VTAs specifically target tumor blood

       vessels, the fusion proteins are intended to affect only the

       established blood vessels that are essential for the survival and

       growth of tumors.  Researchers reported on their progress in

       successfully developing and testing a series of VTA coaguligands that

       currently are in further testing in animal cancer models.


    *  Peregrine researchers gave an oral presentation on novel methods the

       company is employing in its drug discovery efforts for its VEA program.

       VEAs are a new class of therapeutics comprised of tumor-specific

       antibodies fused to vasoactive compound
'"/>




Page: 1 2 3 4 5 6 7 
Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in
Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That
Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model
Reported by Peregrine
3. Data Presented at AACR Meeting Shows Peregrines Immunocytokine
Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in
Preclinical Studies
4. Data Presented at AACR Meeting Show Peregrines Bavituximab
Equivalent Can Generate Curative Immune Responses as Part of a
Vaccine-Like Regimen in Preclinical Models of Aggressive Brain
Cancer
5. Data Presented at AACR Meeting Shows Peregrines Selective
Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical
Cancer Models
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference